Sector
PharmaceuticalsOpen
₹226.1Prev. Close
₹225.53Turnover(Lac.)
₹4,220.43Day's High
₹229.4Day's Low
₹223.9552 Week's High
₹307.952 Week's Low
₹129.1Book Value
₹53.77Face Value
₹10Mkt Cap (₹ Cr.)
30,200.54P/E
43.55EPS
5.18Divi. Yield
0.05Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in these regions.
This month, the US FDA inspected the facility and after inspection issued a Form 483 of six observations as the company has to improve compliance in this regard.
In response to growing demand of IA, capacity expansions are under way at both Dahej and Digwal facilities, with month-on-month production growth.
As part of long-term strategy PCC has seen a number of product launches during recent times which are building block towards market presence in generic injectables.
The transaction falls in the internal transaction category because the parent is trading with a subsidiary.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 1,322.95 | 1,193.32 | 1,185.91 | 994.7 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5,389.12 | 4,068.47 | 3,937.21 | 3,105.92 |
Net Worth | 6,712.07 | 5,261.79 | 5,123.12 | 4,100.62 |
Minority Interest |
No Record Found
No Record Found
No Record Found
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|
Gross Sales | 8,171.16 | 7,081.55 | 6,559.1 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 8,171.16 | 7,081.55 | 6,559.1 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 234.88 | 279.44 | 334.83 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Nandini Piramal
Executive Director & CEO
PETER D DEYOUNG
Non Executive Director
Neeraj Bharadwaj
Independent Director
Jairaj Purandare
Independent Director
S Rama Dorai
Independent Director
Peter Stevenson
Independent Director
Sridhar Gorthi
Independent Director
Vibha Paul Rishi
Executive Director & CFO
Vivek Valsaraj
Company Sec. & Compli. Officer
Tanya DCosta
Additional Director
Nathalie Leitch
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Piramal Pharma Ltd
Summary
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan(now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. PPL holds 49% of the paid-up equity share capital in the joint venture. Further, PPL has a minority investment of 33.33% in Yapan Bio that operates in the biologics/ bio-therapeutics and vaccine segments. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Littles, Tetmosol, i-Pill and Polycrol.Apart from this, the Company offers differentiated capabilities in niches areas suc
Read More
The Piramal Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹227.8 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Piramal Pharma Ltd is ₹30200.54 Cr. as of 02 Apr ‘25
The PE and PB ratios of Piramal Pharma Ltd is 43.55 and 4.26 as of 02 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Piramal Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Piramal Pharma Ltd is ₹129.1 and ₹307.9 as of 02 Apr ‘25
Piramal Pharma Ltd's CAGR for 5 Years at N/I%, 3 Years at 6.72%, 1 Year at 73.62%, 6 Month at -1.43%, 3 Month at -12.67% and 1 Month at 18.23%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.